Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
Department of Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy.
Nephrol Dial Transplant. 2019 Apr 1;34(4):587-596. doi: 10.1093/ndt/gfy064.
Complement is thought to play a role in immunoglobulin A nephropathy (IgAN), though the activating mechanisms are unknown. This study focused on the gene expression of CD46 and CD55, two key molecules for regulating C3 convertase activity of lectin and alternative complement pathways at a cellular level.
The transcriptional expression in peripheral white blood cells (WBCs) of CD46 and CD55 was investigated in 157 patients enrolled by the Validation of the Oxford Classification of IgAN group, looking for correlations with clinical and pathology features and estimated glomerular filtration rate (eGFR) modifications from renal biopsy to sampling. Patients had a previous median follow-up of 6.4 (interquartile range 2.8-10.7) years and were divided into progressors and non-progressors according to the median value of their velocity of loss of renal function per year (-0.41 mL/min/1.73 m2/year).
CD46 and CD55 messenger RNA (mRNA) expression in WBCs was not correlated with eGFR values or proteinuria at sampling. CD46 mRNA was significantly correlated with eGFR decline rate as a continuous outcome variable (P = 0.014). A significant difference was found in CD46 gene expression between progressors and non-progressors (P = 0.013). CD46 and CD55 mRNA levels were significantly correlated (P < 0.01), although no difference between progressors and non-progressors was found for CD55 mRNA values. The prediction of progression was increased when CD46 and CD55 mRNA expressions were added to clinical data at renal biopsy (eGFR, proteinuria and mean arterial blood pressure) and Oxford MEST-C (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, presence of any crescents) score.
Patients with progressive IgAN showed lower expression of mRNA encoding for the complement inhibitory protein CD46, which may implicate a defective regulation of C3 convertase with uncontrolled complement activation.
补体被认为在免疫球蛋白 A 肾病(IgAN)中起作用,尽管其激活机制尚不清楚。本研究重点关注细胞水平上调节经典和替代补体途径 C3 转化酶活性的关键分子 CD46 和 CD55 的基因表达。
通过牛津 IgAN 分类验证组纳入的 157 例患者,研究外周血白细胞(WBC)中 CD46 和 CD55 的转录表达,寻找与临床和病理特征以及从肾活检到取样的估计肾小球滤过率(eGFR)改变的相关性。患者的中位随访时间为 6.4 年(四分位距 2.8-10.7 年),根据每年肾功能丧失速度的中位数(-0.41ml/min/1.73m2/年)将其分为进展组和非进展组。
WBC 中 CD46 和 CD55 的信使 RNA(mRNA)表达与取样时的 eGFR 值或蛋白尿均无相关性。CD46 mRNA 与连续变量 eGFR 下降率显著相关(P=0.014)。进展组和非进展组之间 CD46 基因表达存在显著差异(P=0.013)。虽然未发现 CD55 mRNA 值在进展组和非进展组之间存在差异,但 CD46 和 CD55 mRNA 水平显著相关(P<0.01)。当将 CD46 和 CD55 mRNA 表达与肾活检时的临床数据(eGFR、蛋白尿和平均动脉压)和牛津 MEST-C(系膜细胞增生、内皮下细胞增生、节段性肾小球硬化、肾小管萎缩/间质纤维化、新月体存在)评分一起加入时,对进展的预测能力增加。
进展性 IgAN 患者 CD46 编码补体抑制蛋白的 mRNA 表达较低,这可能表明 C3 转化酶的调节失控,补体激活不受控制。